nach oben

Erschienen in:

08.02.2019 | Original Article

Type 1 and type 2 iodothyronine deiodinases in the thyroid gland of patients with huge goitrous Hashimoto’s thyroiditis

verfasst von: Azusa Harada, Emiko Nomura, Kumiko Nishimura, Mitsuru Ito, Hiroshi Yoshida, Akira Miyauchi, Mitsushige Nishikawa, Ichiro Shiojima, Nagaoki Toyoda

Erschienen in: Endocrine | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The serum free triiodothyronine (FT₃)/free thyroxine (FT₄) ratio in patients with huge goitrous Hashimoto’s thyroiditis (HG-HT) is relatively high. We investigated the cause of high FT₃/FT₄ ratios.

Methods

We measured the serum FT₃, FT₄, and thyrotropin (TSH) levels of seven patients with HG-HT who had undergone a total thyroidectomy. Eleven patients with papillary thyroid carcinoma served as controls. The activities and mRNA levels of type 1 and type 2 iodothyronine deiodinases (D1 and D2, respectively) were measured in the thyroid tissues of HG-HT and perinodular thyroid tissues of papillary thyroid carcinoma.

Results

The TSH levels in the HG-HT group were not significantly different from those of the controls. The FT₄ levels in the HG-HT group were significantly lower than those of the controls, whereas the FT₃ levels and FT₃/FT₄ ratios were significantly higher in the HG-HT group. The FT₃/FT₄ ratios in the HG-HT group who had undergone total thyroidectomy and received levothyroxine therapy decreased significantly to normal values. Both the D1 and D2 activities in the thyroid tissues of the HG-HT patients were significantly higher than those of the controls. However, the mRNA levels of both D1 and D2 in the HG-HT patients’ thyroid tissues were comparable to those of the controls. Interestingly, there were significant correlations between the HG-HT patients’ D1 and D2 activities, and their thyroid gland volume or their FT₃/FT₄ ratios.

Conclusions

Our results indicate that increased thyroidal D1 and D2 activities may be responsible for the higher serum FT₃/FT₄ ratio in patients with HG-HT.

P.R. Larsen, J.E. Silva, M.M. Kaplan, Relationships between circulating and intracellular thyroid hormones: physiological and clinical implications. Endocr. Rev. 2(1), 87–102 (1981)CrossRefPubMed

D.L. St. Germain, V.A. Galton, The deiodinase family of selenoproteins. Thyroid 7(4), 655–668 (1997)CrossRef

A.C. Bianco, D. Salvatore, B. Gereben, M.J. Berry, P.R. Larsen, Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocr. Rev. 23(1), 38–89 (2002)CrossRefPubMed

G.G.J.M. Kuiper, M.H.A. Kester, R.P. Peeters, T.J. Visser, Biochemical mechanisms of thyroid hormone deiodination. Thyroid 15(8), 787–798 (2005)CrossRefPubMed

D. Salvatore, H. Tu, J.W. Harney, P.R. Larsen, Type 2 iodothyronine deiodinase is highly expressed in human thyroid. J. Clin. Invest. 98(4), 962–968 (1996)CrossRefPubMedPubMedCentral

P. Laurberg, H. Vestergaard, S. Nielsen, S.E. Christensen, T. Seefeldt, K. Helleberg, K.M. Pedersen, Source of circulating 3,5,3’-triiodothyronine in hyperthyroidism estimated after blocking type 1 and type 2 iodothyronine deiodinses. J. Clin. Endocrinol. Metab. 92(6), 2149–2156 (2007)CrossRefPubMed

B.W. Kim, G.H. Daniels, B.J. Harrison, A. Price, J.W. Harney, P.R. Larsen, A.P. Weetman, Overexpression of type 2 iodothyronine deiodinase in follicular carcinoma as a cause of low circulating free thyroxine levels. J. Clin. Endocrinol. Metab. 88(2), 594–598 (2003)CrossRefPubMed

A.P. Weetman, C.A. Shepherdley, P. Mansell, C.S. Ubhi, T.J. Visser, Thyroid over-expression of type 1 and type 2 deiodinase may account for the syndrome of low thyroxine and increasing triiodothyronine during propylthiouracil treatment. Eur. J. Endocrinol. 149(5), 443–447 (2003)CrossRefPubMed

Y. Kanou, A. Hishinuma, K. Tsunekawa, K. Seki, Y. Mizuno, H. Fujisawa, T. Imai, Y. Miura, T. Nagasaka, C. Yamada, T. Ieiri, M. Murakami, Y. Murata, Thyroglobulin gene mutations producing defective intracellular transport of thyroglobulin are associated with increased type 2 iodothyronine deiodinase activity. J. Clin. Endocrinol. Metab. 92(4), 1451–1457 (2007)CrossRefPubMed

10.

F.S. Celi, G. Coppotelli, A. Chidakel, M. Kelly, B.A. Brillante, T. Shawker, N. Cherman, P.P. Feuillan, M.T. Collins, The role of type 1 and type 2 5’-deiodinase in the pathophysiology of the 3,5,3’-triiodothyronine toxicosis of McCune-Albright syndrome. J. Clin. Endocrinol. Metab. 93(6), 2383–2389 (2008)CrossRefPubMedPubMedCentral

11.

M. Ito, N. Toyoda, E. Nomura, Y. Takamura, N. Amino, T. Iwasaka, J. Takamatsu, A. Miyauchi, M. Nishikawa, Type 1 and type 2 iodothyronine deiodinases in the thyroid gland of patients with 3,5,3’-triiodothyronine-predominant Graves’ disease. Eur. J. Endocrinol. 164(1), 95–100 (2011)CrossRefPubMed

12.

N. Toyoda, E. Nomura, M. Ito, A. Harada, K. Nishimura, C. Ukita, T. Iwasaka, S. Kubota, A. Miyauchi, M. Nishikawa, Type 2 iodothyronine deiodinase activity is highly expressed in the large goiter with Hashimoto’s thyroiditis. Program of the 14th International Congress of Endocrinology. The Japan Endocrine Society (Kyoto, Japan, 2010), p S478, (Abstract P4-16-2)

13.

Y. Murakami, J. Takamatsu, S. Sakane, K. Kuma, N. Ohsawa, Changes in thyroid volume in response to radioactive iodine for Graves’ hyperthyroidism correlated with activity of thyroid-stimulating antibody and treatment outcome. J. Clin. Endocrinol. Metab. 81(9), 3257–3260 (1996)PubMed

14.

D. Bellabarba, R.E. Peterson, K. Sterling, An improved method for chromatography of iodothyronines. J. Clin. Endocrinol. Metab. 28(2), 305–307 (1968)CrossRefPubMed

15.

M. Ito, A. Miyauchi, S. Morita, T. Kudo, E. Nishihara, M. Kihara, Y. Takamura, Y. Ito, K. Kobayashi, A. Miya, S. Kubota, N. Amino, TSH-suppresive dose of levothyroxine are required to achieve preoperative native serum triiodothyronine levels in patients who have undergone total thyroidectomy. Eur. J. Endocrinol. 167(3), 373–378 (2012)CrossRefPubMed

16.

B. Gereben, C. Goncalves, J.W. Harney, P.R. Larsen, A.C. Bianco, Selective proteolysis of human type 2 deiodinase: a novel ubiquitin-proteasomal mediated mechanism for regulation of hormone activation. Mol. Endocrinol. 14(11), 1697–1708 (2000)CrossRefPubMed

17.

Y. Imai, N. Toyoda, A. Maeda, T. Kadobayashi, F. Wang, K. Kuma, M. Nishikawa, T. Iwasaka, Type 2 iodothyronine deiodinase expression is upregulated by the protein kinase A-dependent pathway and is downregulated by the protein kinase C-dependent pathway in cultured human thyroid cells. Thyroid 11(10), 899–907 (2001)CrossRefPubMed

18.

D.L. Germain, Dual mechanisms of regulation of type I iodothyronine 5’-deiodinase in the rat kidney, liver, and thyroid gland. Implic. Treat. hyperthyroidism Radiogr. Contrast Agents J. Clin. Invest. 81(5), 1476–1484 (1988)

19.

A.P. Weetman, in Werner & Ingbar’s The Thyroid, ed. by L.E. Braverman, D.S. Cooper, D.S. (eds.) 10th edn. (Lippincott Williams & Willkins, Philadelphia, 2013), pp. 525–535

20.

A.L. Maia, B.W. Kim, S.A. Huang, J.W. Harney, P.R. Larsen, Type 2 iodothyronine deiodinase is the major source of plasma T₃ in euthyroid humans. J. Clin. Invest. 115(9), 2524–2533 (2005)CrossRefPubMedPubMedCentral

Titel: Type 1 and type 2 iodothyronine deiodinases in the thyroid gland of patients with huge goitrous Hashimoto’s thyroiditis
verfasst von: Azusa Harada
Emiko Nomura
Kumiko Nishimura
Mitsuru Ito
Hiroshi Yoshida
Akira Miyauchi
Mitsushige Nishikawa
Ichiro Shiojima
Nagaoki Toyoda
Publikationsdatum: 08.02.2019
Verlag: Springer US
Erschienen in: Endocrine / Ausgabe 3/2019
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-019-01855-7

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

23.04.2024 | Ablationstherapie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Type 1 and type 2 iodothyronine deiodinases in the thyroid gland of patients with huge goitrous Hashimoto’s thyroiditis

Abstract

Purpose

Methods

Results

Conclusions

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Hinter dieser Appendizitis steckte ein Erreger

Demenzkranke durch Antipsychotika vielfach gefährdet

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2019

Elevated 1-h post-load plasma glucose is associated with right ventricular morphofunctional parameters in hypertensive patients

IGF and mTOR pathway expression and in vitro effects of linsitinib and mTOR inhibitors in adrenocortical cancer

Association and gene–gene interaction analyses for polymorphic variants in CTLA-4 and FOXP3 genes: role in susceptibility to autoimmune thyroid disease

Expression and clinicopathological role of miR146a in thyroid follicular carcinoma

A cure model survival analysis of patients affected by small intestinal neuroendocrine neoplasms: the Bologna ENETS center experience

Dysbiosis of the gut microbiome is associated with thyroid cancer and thyroid nodules and correlated with clinical index of thyroid function

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Hinter dieser Appendizitis steckte ein Erreger

Demenzkranke durch Antipsychotika vielfach gefährdet

Update Innere Medizin